



## CareDx Testing Solutions for Lung Transplant Recipients

- The published peer-reviewed data supports the guidance that AlloSure Lung may be used in a broad range of patients, including patients of varying risk profiles and ethnic demographics. ([Keller, et al.](#))
- The evidence clearly indicates that AlloSure Lung can be applied for both for-cause and surveillance use. ([Sayah et al.](#); [Khush et al.](#); [Keller, et al.](#))
- There is high confidence in AlloSure Lung, based on the analytical validation studies demonstrating high precision and the reproducibility of the optimal cutoff for distinguishing rejection from no-rejection (0.87%, 0.85%, and 0.91%, respectively). ([Sayah et al.](#); [Khush et al.](#); [Keller, et al.](#))
- The Keller 2022 multicenter clinical utility study demonstrated a reduction in biopsies by 82% when managed with a surveillance regiment using AlloSure Lung compared to a historical control in which patients underwent invasive surveillance biopsies. ([Keller, et al.](#))
- When used for surveillance, AlloSure Lung was able to identify subclinical/asymptomatic acute lung allograft dysfunction (ALAD) - defined as a composite outcome of ACR, AMR, or infection - in 8% of visits where AlloSure Lung was assessed. ([Keller, et al.](#))